Paladin Labs, Inc. has entered an agreement to acquire Labopharm in transaction valued at approximately $20.5 million. Labopharm’s board of directors has approved the transaction.   “The offer from Paladin provides compelling value, certainty and liquidity to our shareholders,” said Santo J. Costa, chairman of the Labopharm board. “Following a comprehensive review of alternatives under the previously announced strategic review, the Board of Directors has concluded that this al...